These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 3669156)

  • 1. The role of oxalate and calcium oxalate activity and formation product ratio in patients with renal stones before and during treatment.
    Peña JC; Monforte MF; Briceño A
    J Urol; 1987 Nov; 138(5):1137-40. PubMed ID: 3669156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hydrochlorothiazide therapy on the crystallization of calcium oxalate in urine.
    Woelfel A; Kaplan RA; Pak CY
    Metabolism; 1977 Feb; 26(2):201-5. PubMed ID: 834153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers.
    Favus MJ; Coe FL
    Scand J Urol Nephrol Suppl; 1980; 53():265-71. PubMed ID: 6938003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can 24-hour urine stone risk profiles predict urinary stone composition?
    Torricelli FC; De S; Liu X; Calle J; Gebreselassie S; Monga M
    J Endourol; 2014 Jun; 28(6):735-8. PubMed ID: 24460026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in inhibitory potential in urine of hyperuricosuric calcium oxalate stone formers effected by allopurinol and orthophosphates.
    Goldwasser B; Sarig S; Azoury R; Wax Y; Hirsch D; Perlberg S; Many M
    J Urol; 1984 Nov; 132(5):1008-11. PubMed ID: 6492268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Physicochemical basis for the formation of calcium oxalate renal stones. Estimation of the degree of urine saturation with the activity product ratio (CPA) (author's transl)].
    Peña JC; Fishleder S; Galván P; Herrera-Acosta J
    Rev Invest Clin; 1981; 33(4):333-41. PubMed ID: 7330508
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibitory activity of whole urine: a comparison of urines from stone formers and healthy subjects.
    Ryall RL; Hibberd CM; Mazzachi BC; Marshall VR
    Clin Chim Acta; 1986 Jan; 154(1):59-67. PubMed ID: 3943225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine composition in patients with renal stone disease during treatment with allopurinol.
    Tiselius HG; Larsson L
    Scand J Urol Nephrol; 1980; 14(1):65-71. PubMed ID: 7375845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorptive hyperoxaluria: a new clinical entity--successful treatment with hydrochlorothiazide.
    Yendt ER; Cohanim M
    Clin Invest Med; 1986; 9(1):44-50. PubMed ID: 3955921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary excretion of oxalate by patients with renal hypercalciuric stone disease. Effect of chronic treatment with hydrochlorothiazide.
    Urivetzky M; Braverman S; Motola JA; Smith AD
    Urology; 1991 Apr; 37(4):327-30. PubMed ID: 2014597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation.
    Nicar MJ; Hill K; Pak CY
    Metabolism; 1983 Sep; 32(9):906-10. PubMed ID: 6888271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease.
    Baggio B; Gambaro G; Favaro S; Borsatti A
    Nephron; 1983; 35(1):11-4. PubMed ID: 6888620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.
    Krieger NS; Asplin JR; Frick KK; Granja I; Culbertson CD; Ng A; Grynpas MD; Bushinsky DA
    J Am Soc Nephrol; 2015 Dec; 26(12):3001-8. PubMed ID: 25855777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of amiloride with or without hydrochlorothiazide on urinary calcium and saturation of calcium salts.
    Leppla D; Browne R; Hill K; Pak CY
    J Clin Endocrinol Metab; 1983 Nov; 57(5):920-4. PubMed ID: 6619267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy, calcium oxalate urolithiasis.
    Ruml LA; Pearle MS; Pak CY
    Urol Clin North Am; 1997 Feb; 24(1):117-33. PubMed ID: 9048856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graphic display of urinary risk factors for renal stone formation.
    Pak CY; Skurla C; Harvey J
    J Urol; 1985 Nov; 134(5):867-70. PubMed ID: 4057368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder.
    Coe FL
    Ann Intern Med; 1977 Oct; 87(4):404-10. PubMed ID: 907239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium restriction, thiazide, citrate, and allopurinol in calcium oxalate nephrolithiasis.
    Coe FL
    Acta Urol Belg; 1994 Jun; 62(2):25-9. PubMed ID: 8037000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.